TCTR20211004001
Completed
Not Applicable
Immunogenicity and safety of an intradermal boost in healthy general population; preliminary study (COVID-19)
faculty of medicine, Prince of songkla university0 sites240 target enrollmentOctober 4, 2021
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- faculty of medicine, Prince of songkla university
- Enrollment
- 240
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Thai adults aged 18\-60 years, who have been completed two\-dose regimen of inactive SARS\-CoV\-2 vaccine in the past 1 \- 3 months
- •2\. The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 3\-month follow\-up of the study.
- •3\. Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization
- •4\. The subject can provide with informed consent and sign informed consent form (ICF).
Exclusion Criteria
- •1\. Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.
- •2\. Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination.
- •3\. Women with positive urine pregnancy test, pregnant or breast\-feeding, or have a pregnancy plan within six months of after baseline period.
- •4\. Have infectious diseases, including HIV and SARS\-CoV\-2 infection.
- •5\. Have history of SARS\-CoV\-2 infection
- •6\. Have severe chronic diseases or condition in progress cannot be controlled. For examples, poor controlled DM and uncontrolled HT.
- •7\. Have the history of urticaria 1 year before receiving the investigational vaccine.
- •8\. Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection).
- •9\. Have needle sickness.
- •10\. Have the history of immunosuppressive therapy, cytotoxic therapy or systemic corticosteroids
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adultsinfantile paralysispolio10047438NL-OMON32437ederlands Vaccin Instituut120
Active, not recruiting
Not Applicable
Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults - Intradermal injection of reduced dose IPV in adultsEUCTR2009-015175-27-NLetherlands Vaccine Institute
Completed
Not Applicable
Onderzoek naar de bijwerkingen en immuunrespons na een boostervaccinatie tegen polio, toegediend met een naaldloze Jet Injector.poliomyelitis, polio, vaccination, vaccinatie, intradermal, intradermaal, jet injector, needle-free, naaldloosNL-OMON26044etherlands Vaccine Institute RIVM, formerly Nederland Vaccine, Institute (NVI)120
Recruiting
Phase 4
Intradermal booster COVID-19 vaccinatioIntradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2booster vaccine, third dose, SAR-CoV2, older adultTCTR20220112002Faculty of Medicine Siriraj Hospital, Mahidol University210
Active, not recruiting
Not Applicable
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in MexicoPrevention of symptomatic dengue diseaseTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2014-001736-11-Outside-EU/EEASanofi Pasteur SA732